Enliven Therapeutics, Inc. (ELVN) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • No revenue • High cash burn ELVN is conservatively capitalized with large cash and investments and almost no debt, but zero revenue and steep operating losses are producing significant cash burn and negative returns.
Price Behavior
Key Price Behavior Insights: • Above last-month MA • RSI near-oversold • Resistance at $39–$40 Support Level: $27.25–$28.00 Resistance Level: $39.20–$40.00 After a strong late‑March rebound the stock trades above its last month simple moving average, signaling short-term bullish momentum but with RSI near 25 and March's sharp volatility meaning downside risk unless it clears $39–$40 or holds above ~$27.
Sentiment & News
Key News Insights: • Analyst optimism • 52‑week high • CMO share sale Enliven saw strong analyst optimism with a $41 12‑month consensus and a spike to a 52‑week high amid heavy volume, while a material CMO share sale materially reduced her direct stake.
AI Summary
ELVN should be viewed less as a balance‑sheet survival speculative biotech and more as a high‑conviction, event‑driven execution play—Phase 1b ENABLE materially de‑risks ELVN‑001 and the ~$460M cash runway funds near‑term Phase‑3/commercial prep, so investors should prioritize Phase‑3 design/timing and spend, partnership/non‑dilutive financing, and monitor insider selling/17% short interest as primary downside catalysts.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |